Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial.

导出 LinkOut

翻译打印收藏纠错

作者： Tingmin,Yu ^[1] ; Li,He ^[2] ; Xiaosu,Yang ^[3] ; Jiying,Zhou ^[4] ; Guogang,Luo ^[5] ; Hebo,Wang ^[6] ; Hongru,Zhao ^[7] ; Quan,Hu ^[8] ; Fei,Ji ^[8] ; Shengyuan,Yu ^[9]

作者单位： Department of Neurology, Second Hospital, Jilin University, Changchun, China. ^[1] Department of Neurology, West China Hospital of Sichuan University, Chengdu, China. ^[2] Department of Neurology, Xiangya Hospital, Central South University, Changsha, China. ^[3] Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. ^[4] Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. ^[5] Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, China. ^[6] Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China. ^[7] LCDDMAC, Eli Lilly and Company, Shanghai, China. ^[8] Department of Neurology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. yusy1963@126.com. ^[9]

关键词 5-HT1F receptor agonist Chinese population Consistency Efficacy Lasmiditan Migraine Phase?3

DOI 10.1007/s40120-022-00369-1

PMID 35713760

发布时间 2022-08-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Neurology and therapy

2022年11卷3期

1269-1283页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial.

Neurology and therapy

相似文献

Neurology and therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial.

Neurology and therapy

相似文献

Neurology and therapy

相关期刊

检索历史清除